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provided an opportunity to gather experts from within and outside ophthalmology to develop strategies to
address drug delivery to posterior intraocular tissues—a topic of great interest, as the major route of drug
delivery is via intravitreous injection.
Disciplines
Medicine and Health Sciences | Ophthalmology | Pharmaceutics and Drug Design | Veterinary Medicine
Comments
Gustavo D. Aguirre is not listed as an individual author on this paper but is part of the Third ARVO/Pfizer
Research Institute Working Group. A full list of the Third ARVO/Pfizer Research Institute Working Group
members for this paper can be found on p.4713.
This journal article is available at ScholarlyCommons: https://repository.upenn.edu/vet_papers/110
Drug Delivery to Posterior Intraocular Tissues: Third Annual
ARVO/Pfizer Ophthalmics Research Institute Conference
Henry F. Edelhauser1, Jeffrey H. Boatright1, John M. Nickerson1, and Third ARVO/Pfizer
Research Institute Working Group2
1From the Department of Ophthalmology, Emory University, Atlanta, Georgia
The third Annual ARVO/Pfizer Ophthalmic Research Institute Conference was held Friday
and Saturday, May 4 and 5, 2007 at the Fort Lauderdale Grande Hotel and Yacht Club, Fort
Lauderdale, Florida. The conference, funded by the ARVO Foundation for Eye Research
through a grant from Pfizer Ophthalmics, provided an opportunity to gather experts from within
and outside ophthalmology to develop strategies to address drug delivery to posterior
intraocular tissues—a topic of great interest, as the major route of drug delivery is via
intravitreous injection.
A working group of 33 participants, focused interdisciplinary contributors, 19 observers from
ARVO/Pfizer, and clinical and basic ophthalmic researchers convened to identify (1) unmet
patient needs regarding current drug delivery, novel treatment of retinal diseases, the potential
for novel drug design opportunities, drug delivery methods for targeted localized and sustained
release, and delivery of macromolecules (siRNA, DNA); and (2) to evaluate the usefulness of
nanoparticles, microbeads, and implants for drug delivery, as well as physical means of drug
delivery (ionophoresis, electroporation, and microneedles).
Session I: Unmet Needs and New Drug Opportunities in Treating Disorders of the
Posterior Segment
Session II: Animal Models of Posterior Ocular Diseases
Session III: New Drug Design and Delivery Systems: What Do Experts See Beyond the
Horizon?
Session IV: Ocular Drug Delivery Using Nanoparticles, Microbeads, and Microneedles
Session V: Transscleral, Intravitreous, and Suprachoroidal Drug Delivery
Session VI: Ocular Tissue Dissection, Modeling, and Ocular Tissue Assays
Session VII: Iontophoresis, Electroporation, Electrophoresis, and Photo-acoustic Delivery
Each session began with a 10-minute introduction followed by a 30-minute lecture by a
distinguished expert. Allan S. Hoffman, ScD, Professor of Bioengineering at the University of
Washington, Seattle, presented “Design of Polymer Carriers for Intracellular Delivery of
Biomolecular Drugs” and Mansoor Amiji, RPh, PhD, Professor and Associate Chairman of
Pharmaceutical Science at Northeastern University (Boston, MA), presented “Nanotechnology
for Advanced Drug Delivery.”
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During the remainder of each session, participants, and attendees discussed pertinent questions,
voiced opinions, and identified unanswered questions. These discussions confirmed current
and future needs for ocular drug delivery to the posterior segment.
Ocular Drug Delivery Overview
Paul Sternberg, Jr, MD, summarized the clinical perspective of ocular drug delivery.
Traditional means of drug delivery to the eye have involved topical medications, applied either
in eye-drop or ointment form, supplemented with systemic medications such as antibiotics or
corticosteroids. To achieve higher intraocular penetration, physicians began using
subconjunctival and then sub-Tenon injections. However, it was demonstrated in the 1980s
that adequate levels of antibiotics to treat endophthalmitis were achievable only with
intravitreous injection. The Endophthalmitis Vitrectomy Study showed that supplemental use
of intravenous antibiotics did not offer additional benefit. With the emergence of infectious
retinitis associated with AIDS and the need for chronic antiviral therapy, investigators
developed the Vitrasert (Bausch & Lomb, Rochester, NY), the first FDA-approved device for
sustained delivery of intraocular medication. Many chronic ocular diseases require long-term
therapy (glaucoma, AMD, diabetic retinopathy, uveitis, intraocular malignancy); review of the
recent literature reveals a dramatic increase in studies evaluating novel methods for drug
delivery.1–3
Clinicopathologic considerations of drug delivery for posterior segment diseases was
summarized by Hans Grossniklaus, MD, MBA. Posterior segment diseases may generally be
classified as inflammations, degenerations, and neoplasms. Drug delivery should be targeted
to a particular coat (layer) of the eye, including the outer coat (sclera/cornea), middle coat
(uveal tract), inner coat (retina), and vitreous. Posterior segment drug delivery for inflammatory
conditions, both noninfectious and infectious, should minimize collateral damage, and duration
should be timed in accordance with the acute or chronic nature of the disease. In proliferative
diabetic retinopathy, drugs may be delivered via and/or targeted to neovascular tissue. In
choroidal neovascularization (CNV), such as occurs in age-related macular degeneration
(AMD), the growth pattern and stage of the CNV should be considered when designing drug
delivery strategies. For instance, occult CNV grows between the retinal pigment epithelium
(RPE) and Bruch's membrane; thus, transscleral or transuveal delivery may be desirable.
However, classic CNV grows between the RPE and neurosensory retina; thus, transvitreal or
subretinal delivery may be desirable. Typical CNV in patients with AMD has both sub-RPE
and subretinal components. Primary intraocular large cell lymphoma grows within the retina
around vascular channels and in the sub-RPE space, where it receives nutrition from the
choriocapillaris. Lymphoma cells become apoptotic at approximately 90 to 110 μm external
to the retinal vessels in the vitreous and choriocapillaris in the sub-RPE space, thus limiting
the utility for local drug delivery. Similarly, retinoblastoma typically becomes necrotic at the
same distance from its vascular supply, thus enabling the efficacy of systemic chemoreduction
therapy in combination with local therapy. The exception in retinoblastoma is intravitreous
seeding, which is notoriously unresponsive to chemoreduction and local therapy. Local
carboplatin injection for intravitreous seeds may lead to ischemic optic neuropathy, thus
indicating that advances in local drug delivery are necessary. In most instances, uveal
melanoma may be locally controlled with radioactive plaque brachytherapy, proton beam
irradiation, and/or TTT. However, exceptions include plaque failures, collateral radiation,
retinopathy/optic neuropathy, and TTT failures, thus favoring the utility of local drug delivery.
Local drug delivery must be superior to currently available treatments, cause minimal collateral
damage, and be based on the pathobiology of the disease.
2007 Third ARVO/Pfizer Ophthalmics Research Institute Working Group Participants
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Unmet Needs and New Drug Opportunities in Treating Disorders of the
Posterior Segment
George Williams, MD, emphasized the need for advances in drug delivery to treat retinal
disease. Diseases of the posterior segment represent the leading cause of visual impairment
and blindness in the United States. Until recently, treatment of most posterior segment disorders
has been primarily surgical: laser photocoagulation for retinal vascular disease and vitrectomy
for vitreopathies. Over the past few years, improved understanding of the pathophysiology of
many retinal diseases has led to development of effective novel drug therapies, which in some
diseases have replaced surgical therapies and in others, complement surgery. Increasingly, the
combination of surgery and drug-based therapy addresses retinal disease at both the anatomic
and molecular level, resulting in improved visual outcomes.
Despite the relative success of these novel drugs, important problems and new issues related
to drug delivery remain. The explosion in the use of intravitreous drugs carries the potential
of ocular and even systemic complications. The need for repeated intravitreous injections over
the course of months and years creates a significant treatment burden for patients and their
families. Improved drug delivery technologies that provide optimal pharmacokinetics, dose
intervals, and less invasive routes of administration are needed.
Interdisciplinary Contributors
Mansoor Amiji, Northeastern University, Boston, MA
Allan Hoffman, University of Washington, Seattle, WA
Kevin Li, University of Cincinnati, Cincinnati, OH
Paul Missel, Alcon Research, Ltd., Fort Worth, TX
Mark Prausnitz, Georgia Institute of Technology, Atlanta, GA
Observers
Jessica Ballinger, Pfizer Ophthalmics, New York, NY
Amir Bar-Ilan, QBI Enterprises Ltd, Nes Ziona, Israel
Kristine Erickson, Toxikon Corp., Bedford, MA
Frederick Ferris, III, NEI, Bethesda, MD
Donald Fox, University of Houston, Houston, TX
Karl Gelotte, Pfizer Ophthalmics, New York, NY
Cynthia Grosskreutz, Massachusetts Eye & Ear Infirmary, Boston, MA
Val Harding, Pfizer Ophthalmics, New York, NY
Raymond Iezzi, Wayne State University, Detroit, MI
Martine Jager, Leiden University Medical Center, Leiden, The Netherlands
Hyuncheol Kim, NEI, Bethesda, MD
Philippe Margaron, QLT Inc., Vancouver, BC, Canada
Todd Margolis, University of California-San Francisco, San Francisco, CA
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Tuyen Ong, Pfizer Ophthalmics, San Diego, CA
Dario Paggiarino, Pfizer Ophthalmics, San Diego, CA
Chris Paterson, University of Louisville, Louisville, KY
Stella Robertson, Alcon Research, Ltd, Fort Worth, TX
Ronald Silverman, Weill Medical College of Cornell University, New York, NY.
Imaging technologies such as ocular coherence tomography now provide a reproducible,
quantitative method of assessing therapeutic response to drug therapy at the anatomic level.
Unfortunately, anatomic improvement commonly does not correlate with improved visual
function. Better comprehension of the mechanisms underlying poor visual function after
anatomically successful treatment is necessary for the development of novel drug therapies
that will enhance efficacy and improve safety.
Novel drug treatments for retinoblastoma were reviewed by Joan O'Brien, MD. Local delivery
of drugs to the eye is a goal for all ocular therapies that demonstrate significant systemic toxicity
when delivered intravenously. Avoiding intraocular injection is especially important in the
management of retinoblastoma, in which violation of the ocular barriers has resulted in disease
dissemination. Data were presented on two chemotherapeutic agents, carboplatin and
topotecan, delivered in fibrin sealant for treatment of transgenic (LHβ-Tag) retinoblastoma-
bearing mice. Both agents demonstrated significant therapeutic efficacy in this murine model,
but did so through distinctly different mechanisms of action.
Tim Stout, MD, PhD, MBA, reviewed current mechanisms of control of VEGF gene
expression. Identification of factors that regulate transcription of the vascular endothelial
growth factor (VEGF) gene may help us understand the etiology and progression of
neovascular diseases. Stout and his colleagues have studied in in vitro and in vivo models the
mechanisms through which hypoxia controls VEGF gene transcription. Hypoxia-inducible
factors 1α and 1β stimulate VEGF gene expression via “hypoxia responsive elements” within
the VEGF promoter. Alternative splicing of RTEF transcripts is stimulated by hypoxia; the
resultant RTEF isoforms profoundly affect transcription via SP elements within the VEGF
promoter. Positive and negative regulators of VEGF gene transcription are of therapeutic
interest.
Animal Models of Posterior Ocular Diseases
This session was focused on rodent models of ocular disease, with discussion expanded to large
animal models, including pig and dog.
John Heckenlively, MD, posited that mouse disease models are extremely useful in
understanding human retinal conditions. Human and mouse genomes have high homology,
with some estimates of up to a 95% overlap, such that genetic pathologic findings in mice are
likely to have parallels in humans. Mice have fast generation times and aging, thus reducing
maintenance costs. Possibly most important, custom and controllable mutations can be created
in mice, thus increasing their utility and relevance as models. Heckenlively and collaborators
at The Jackson Laboratory (JAX; Bar Harbor, ME) have identified and characterized over 110
naturally occurring mouse mutants with various heritable ocular diseases or transgenic mice
that were imported by JAX for nonocular conditions but on screening were found to have
hereditary retinal degenerations. Inbred mouse strains and stocks are screened with indirect
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ophthalmoscopy, histology, and electroretinography for visual system diseases. Techniques
for monitoring treatment effects include electroretinography, sweep VEP, multifocal ERG,
VECP, and histology.4,5
A critical point made by Heckenlively is that most murine diseases found to date have
congenital or early-onset manifestations in their human counterpart. The current methodology
of checking younger mice has skewed results. Funding agencies have shown great resistance
to supporting the use of house mice in aging studies (e.g., 2 years). However, when Dr. Bo
Chang of JAX ran a pilot study for 2 years, observing 20 inbred strains that were regarded as
having normal retinas (at younger ages), 15 of those strains developed retinal degenerations
by 18 months.6 Heckenlively suggests that with more patience, allowing investigations of
appropriate mouse strains for at least 2 years, a great deal more can be learned about aging
diseases from mouse models.
Jayakrishna Ambati, MD, addressed mouse models of AMD. He suggested that the major
criterion for usefulness of an animal model is whether it predicts novelties that spark
development of novel diagnosis or clinical treatment approaches. He highlighted the
convergence and divergence of AMD models to and from the clinical phenotype and addressed
the importance of the reproduction of clinical features in fashioning therapeutics. He noted that
identification of the ABCR gene mutation as causative in Stargardt disease7 led to the
development of the rim protein knockout mouse.8 This mouse had an unexpectedly moderate
phenotype, but it provided great insight into the function of rim protein and the understanding
of lipofuscin A2E. This finding in turn led to further study of retinoids and their role in
decelerating the loss of dark adaptation.9,10,11 These studies resulted in a clinical trial to test
retinoid treatment in patients with AMD. Ambati noted that many other mouse models continue
to provide insight into disease and gene function and potential therapies, concluding that the
last decade has witnessed an explosion of rodent models that capture many salient features of
the human condition. These include various laser injury CNV models12–19 combining risk
factors (e.g., aged mice or mice subjected to high fat intake) with genetic lesions,20 iron
transport mutant mice,21 ELOVL4 mutant mice,22–26 and the SOD1 mouse.27
Ambati also discussed his work with mouse strains that are deficient in monocyte
chemoattractant protein-1 (MCP-1, Ccl-2) or its chemokine receptor-2 (Ccr-2). These animals
accumulate lipofuscin in and drusen beneath RPE and exhibit photoreceptor atrophy and CNV.
28 Using this model, his group was able to show that drusen could be cleared ex vivo by wild-
type monocytes (macrophages). More recently, he found that complement activation is present
in AMD drusen and not incidental drusen (thus, it is a possible biomarker). Further, if activation
signaling of complement components is blocked in experimental CNV, neovascularization is
reduced.29 Ccl-2 can be expressed in Ccl2-deficient mice after AAV-mediated gene delivery.
Expression is followed by infiltration of monocytes into Bruch's membrane and reduction of
large sub-RPE deposits. Thus, it seems possible to cause the regression of drusen by using gene
therapy (Kleinman ME, et al. IOVS 2007;48:ARVO E-Abstract 2354).
Steven Bernstein, MD, PhD, spoke about the development of models of anterior ischemic optic
neuropathy (AION). AION is an optic nerve (ON) stroke, resulting from sudden ischemia-
induced functional disruption in the anterior portion of the ON near the ON-retina junction.
There are two forms of AION: (1) arteritic (AAION), involving autoimmune-mediated
thrombosis of the short posterior ciliary arteries and vessels supplying both the retina and ON,
and (2) nonarteritic (NAION), apparently involving only the vascular supply to the anterior
ON. In AAION, outer retinal blood flow and function are affected, whereas in NAION, ON
dysfunction is isolated.
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An earlier AAION model involved destroying the short posterior ciliary arteries, which
requires major orbital surgery, with variable changes in choroidal flow. Bernstein's team
recently generated the first rodent and primate models of NAION, which closely resemble the
human condition and involve selective photothrombosis of the ON capillaries without
significant compromise of inner or outer retinal circulation (Bernstein SL, et al. IOVS
2007;48:ARVO E-Abstract 4410).30–33 Because ON is actually a white matter central nervous
system (CNS) tract, this newer model is the first in vivo isolated CNS white matter stroke
model, with the added advantage that it enables direct, precise evaluation of neuroprotective
mechanisms and drugs to treat the common condition of white matter infarcts, not just the eye.
32 The models include mice, rats, and nonhuman primates. The mouse models allow genetic
analysis of specific gene contributions to AION susceptibility, progression, and resistance.
There are considerable similarities between the rodent and primate NAION models, but also
some significant differences that may offer different treatment windows.32 Gene expression
studies have revealed several potential intervention points for treatment. These have been
further evaluated using stereologic (statistically driven cell quantification) analyses.31 Early
inflammatory changes are important and may set the stage for success or failure of attempts at
axonal repair and regeneration.
In the general discussions that followed, participants noted that large-animal models are
becoming more viable and clearly are necessary to bridge the gap between rodent models and
humans. Gustavo Aguirre, DVM, discussed the many dog strains that he and collaborators and
other colleagues have developed into useful animal models of ocular diseases, some with
profound impact on clinical treatment.34,35 Timothy Olsen, MD, discussed the advantages of
a pig model for studying pharmacokinetics. The pig sclera is close to the thickness of the human
sclera, and the lens is smaller than the rabbit and more closely resembles the human lens.
Choroidal blood flow and retinal pigment epithelium are similar. There are cone cells and an
area centralis (a macular analogue). Porcine retinal vasculature is more analogous to the
vasculature of humans than is that of the rabbit. Systemic pharmacokinetics are similar because
of the body size. Finally, pigs are inexpensive to purchase. Disadvantages include the size of
the animal for housing, high per diems, and lack of inbred strains. In addition, recovery after
some surgical procedures can be difficult because of inflammation.36,37
New Drug Design and Delivery Systems: What Do the Experts See Beyond
the Horizon?
In this session, we concentrated on the delivery of drugs by two unique delivery systems—
polymer carriers and catalytic nanoparticles—and considered transscleral drug delivery.
Allan Hoffman, ScD, is well known for his studies on nanoparticles. His contributions involve
the design of effective polymer carriers for intracellular delivery of biomolecular drugs, such
as peptides, proteins, and nucleic acid drugs; this last category includes plasmid DNA (pDNA
as used in gene therapy), antisense oligodeoxynucleotides (AS-ODNs), and the latest and
“hottest” drug, silencing RNA (siRNA)—also called RNA interference (RNAi). Hoffman and
colleagues are focused on enhancing the effectiveness of intracellular delivery of siRNA, which
remains a major barrier to its use. The group has developed a family of acid-sensitive polymers
that become membrane-disruptive within the acidic environment of the endosome and thereby
enhance the escape of the drug to the cytosol. The “biomimetic” design of these polymers is
based on similarities with fusogenic peptides in the protein coat of some viruses, which fuse
with endosomal membranes at the low pH of the endosome, disrupting the membrane and
allowing the genomic cargo of the virus to escape to the cytosol. The endosomal membrane-
disruptive polymers are incorporated into polymeric micelles for carrying the siRNA into the
cytosol of target cells. A polymeric micelle is formed from a block copolymer of two different
polymers linked together. In this case, the first block is the endosomal membrane–disruptive
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polymer (hydrophilic at pH 7.4, and acting as a stabilizing outer corona of the micelle) linked
to a second block, which is a cationic polymer; this block forms a polyion complex with the
siRNA and thereby forms the insoluble core of the micelle in which the drug is entrapped.
Thus, the polymeric micelle can carry the siRNA and release it in the cytosol of targeted cells
(where the targeting ligand is conjugated to the first block). Hoffman's group is also working
with micelle designs in which the siRNA is conjugated to the second block by a degradable
bond, such as a disulfide bond that will be reduced by glutathione in the cytosol of the target
cell. In that case, the second block is hydrophobic rather than cationic. These innovative and
exciting models hold great promise.
James McGinnis, PhD, described the use of a unique type of nanoparticle for scavenging
reactive oxygen species in the eye. Specifically, these oxide (CeO2) nanoceria particles are
non-toxic and nonimmunogenic, are protective at dosages in the parts-per-billion range, and
have the potential to improve quality of life dramatically for individuals with retinal
degeneration or other neurodegenerative diseases. Unlike other nanoparticles used to deliver
DNA, RNA, protein, or drugs, nanoceria particles are themselves the therapy, as they directly
scavenge the reactive oxygen species. The particles have been shown to provide protection in
vivo in a light-damage animal model. The use of nanoceria particles as a direct therapy for
neurodegenerative diseases represents a novel strategy for protection of the eye against the
generation of reactive oxygen species.
Michael Robinson, MD, lectured on barriers to delivery of drugs by a transscleral route.
Transscleral delivery of drugs into the vitreous using subconjunctival injections may be a safer
alternative for reducing the sight-threatening complications of direct intravitreous injections.
However, subconjunctival injections have demonstrated low and poorly sustained vitreous and
retinal drug levels in animal studies. Transport barriers have been categorized as static,
dynamic, or metabolic barriers, to improve understanding of the clearance mechanisms of drugs
in the subconjunctival space. Static barriers are tissues that the drug diffuses through to reach
the retina (i.e., the sclera, Bruch's membrane, and the retinal pigment epithelium [RPE]).
Traditionally, in vitro models have been used to study the static barriers and measure drug
permeability. Two-chamber in vitro models have demonstrated reasonable permeability of a
several compounds across the sclera and RPE/choroid mounts. However, subsequent
pharmacokinetic studies in live animals typically show low drug concentrations in the retina
for short durations. Tissue permeabilities measured ex vivo do not take into account the effects
of dynamic or physiologic barriers that are present in vivo. In vivo studies are necessary to
examine the dynamic barriers, which include clearance through lymphatic and blood vessels,
bulk fluid flow, and the active transport mechanisms of RPE transporter proteins. Recently,
imaging techniques, such as ocular fluorophotometry and dynamic contrast-enhanced magnetic
resonance imaging (MRI), have been used to assess the relative contribution of each barrier in
the eyes of live animals. The primary dynamic barriers to transscleral drug delivery are the
conjunctival lymphatic/blood vessels and the choroid.38 Both lower the potential for effective
drug delivery to the retina. Surgical techniques can selectively eliminate drug clearance by the
conjunctival vessels and/or the choroid and have been combined with imaging techniques in
vivo to improve understanding of the clearance abilities of the dynamic barriers.
Further development of in vivo models and imaging techniques will improve understanding
of transscleral drug transport. A clear understanding of the dynamic barriers is essential for
successful transscleral drug delivery systems for the treatment of retinal diseases.
Ocular Drug Delivery Using Nanoparticles, Microbeads, and Microneedles
Mansoor M. Amiji, PhD, presented on nanotechnology for advanced drug delivery. He
summarized the era of molecular medicine, which has been accelerated by the human genome
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project and has led to early disease detection through diagnostics and targeted drug and gene
therapy. With the development of nanoparticles, barriers to drug delivery may be overcome at
the organ, tissue, cellular, and subcellular levels. Nano drug delivery may occur through gold
nanospheres and rods, nanowires, nanotriangles, nanostars, nanocubes, and nanorice. The size
of these nano configurations varies from 1 to 100 nm. Nanoplatforms include organic
nanostructures, polymeric nanoparticles, lipid systems-liposomes, self assemblies-micelles,
dendrimers, and carbon nanostructure-nanotubes. Inorganic nanostructures include metal
nanoparticles and nanoshells, silicon nanostructure, nanocrystals, and quantum dots. Hybrid
nanostructures, combining two to three of those previous listed can also be produced.
Studies were described in which polymeric nanoparticles were used for tumor-targeted delivery
to block tumor blood vessels39 and to mediate in vitro drug delivery of tamoxifen and paclitaxel
in human cancer xenograph models.40,41 Gelatin-based engineered nanoparticles have been
used for gene delivery42 and multifunctional nanoemulsions for oral and intravenous delivery.
43 Gadolinium-loaded nanoemulsion has been used in animals for brain imaging, and this
technology could easily be used for imaging within the eye to observe the results of various
drug delivery modalities. Finally, gold nanostructures have been developed for OCT imaging
along with superparamagnetics from oxide-gold-core–shelled nanoparticles (60-nm iron oxide
nanoparticle with 5-nm gold shells) for MRI imaging.
Uday B. Kompella, PhD, spoke about reserved drug and nanotechnology for gene delivery to
the eye. Viral vectors, although more efficient in gene transfection compared to nonviral
vectors, are associated with side effects and risks that make them less attractive for
pharmaceutical product development. Nonviral vectors such as polymer and protein-based
nanoparticles offer a viable pharmaceutical alternative. The factors limiting the success of
nonviral vectors include poor cellular and nuclear entry, low plasmid loading residual organic
solvents, or positive charge of the vector. To overcome limitations of nonviral vectors,
conventional, and supercritical fluid technologies have been used to develop pharmaceutically
acceptable biodegradable polymers and naturally occurring proteins—bioengineered
nanoparticles. Some of the engineered nanoparticles prepared using conventional methods
allow enhanced cellular entry and others prepared using supercritical fluid technology allow
high plasmid loading and sustained plasmid release. Kompella outlined approaches for
preparing nanoparticulate systems by using conventional and supercritical fluid technologies
and presented evidence of the usefulness of nanoparticle gene delivery systems for inhibiting
corneal angiogenesis and expressing superoxide dismutase in the retina.
Current developments in microneedles for ocular drug delivery were reviewed by Mark
Prausnitz, PhD. Traditional methods of ocular drug delivery include topical application,
intraocular injection, and systemic administration. However, each method has limitations in
efficient delivery of drugs to the back of the eye. The Prausnitz laboratory has adapted
microfabrication technology to develop microscopic needles that penetrate only hundreds of
micrometers into the ocular tissue via the cornea or sclera to deliver drugs in a minimally
invasive manner. Prausnitz described (1) hollow microneedles used for microinfusion of a drug
solution into the sclera, (2) solid microneedles coated with drug formulations that rapidly
release drug coatings by dissolution within the ocular tissue, and (3) hollow microneedles for
intrascleral microinjection. In the latter, a hollow glass microneedle was inserted into human
cadaveric sclera for infusions of sulforhodamine solution, nanoparticle suspension, and
microparticle suspension.
In the assessment of use of solid microneedles for intraocular delivery, solid metal
microneedles coated with sodium fluorescein were inserted into rabbit cornea in vivo. After
needle removal, fluorescein concentration in the anterior segment was measured by
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fluorophotometry for ≤24 hours. Similar experiments were repeated using pilocarpine-coated
microneedles, and the rabbit pupil size was monitored.44
Hollow microneedles may be appropriate for model drug solutions and nanoparticle
suspensions that can be infused into the sclera. Delivery of micrometer-sized particles into the
sclera was improved by breaking down tightly packed collagen or GAG fibers using either
collagenase or hyaluronidase.
When solid metal microneedles were inserted into rabbit sclera in vivo, sodium fluorescein
from the needles completely dissolved within 30 seconds, which resulted in fluorescein
concentrations in the anterior chamber 70 times greater than those achieved with topical
delivery of fluorescein without microneedles. Similarly, microneedle delivery of pilocarpine
caused rapid and extensive pupil constriction. No inflammatory response or other adverse
effects were observed when using microneedles. Microneedles were shown to penetrate the
sclera in vitro and cornea in vivo and to deliver useful quantities of model drugs into the
suprachoroidal space. These studies demonstrate that microneedles may provide a minimally
invasive method for the delivery of drugs into the sclera, to treat diseases in the anterior and
posterior segment and to avoid the complications associated with intraocular injection and
systemic administration.
Transscleral, Intravitreous, and Suprachoroidal Drug Delivery
Anthony Adamis, MD, reviewed current and novel drug treatments for AMD. The ani-VEGF
drugs have quickly become first-line therapeutics in wet AMD. Although these drugs have
greatly improved visual outcomes, treatment burden remains a major problem.45–47 Thus, a
significant advance in the field will likely involve development of extended release
formulations of anti-VEGF drugs, as well as drugs addressing newly identified biological
pathways.17 New targets being addressed in wet AMD clinical trials include PDGF-B,48
α5β1 integrin,49,50 and placental growth factor.51 In dry AMD, much attention is focused on
the complement cascade and its role in inflammation.52–63 Given the chronic nature of dry
AMD, extended release formulations will enhance the viability of pharmacologic compounds.
Dayle H. Geroski, PhD, reviewed transscleral drug delivery. Currently, the treatment of
posterior segment eye disease is limited by the difficulty in delivering effective doses of drugs
to target tissues in the posterior eye. Traditional routes of local ophthalmic delivery (i.e.,
topical) do not yield therapeutic drug levels in the posterior tissues of the eye. The use of
intravitreous injections and devices has been effective; however, these methods are not always
well tolerated by the patient and are not without significant risk. The sclera offers another
vector to obtain therapeutic vitreous and retinal drug concentrations. Delivering drugs across
the permeable sclera would be safer and less invasive than the use of intravitreous devices and
could provide a more effective retinal dose than does systemic or topical delivery. Geroski's
laboratory is investigating the potential for delivering drugs across the sclera.63 The relatively
high scleral permeability—compared to the cornea—suggests great potential for development
of methods for transscleral drug delivery, especially for compounds that must be administered
to the posterior part of the eye. In addition, the sclera provides a large surface area of 17
cm2; it comprises 95% of the surface area of the human eye. This large area not only provides
a large region for transscleral drug absorption, but also offers the possibility of delivering
neuroprotective agents, antioxidants, or angiostatic agents to specific regions of the retina.64
Previous in vitro permeability studies from this laboratory have shown the sclera to be
permeable to a wide molecular weight range of solutes.65 Solutes traverse the sclera mainly
by passive diffusion through the aqueous pathways between collagen fibrils. The porosity of
this fiber matrix is the primary determinant of the rate of drug permeation across the sclera.
For any given solute, therefore, the molecular size and radius of the solute are the most
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important determinants of its transscleral permeability. High-molecular-weight compounds
(e.g., FITC-dextran, 150 kDa) that would not be able to reach the chorioretinal tissues after
intravitreous administration because of the barrier provided by the internal limiting membrane
can diffuse through human scleral tissue.66 Solute diffusion across the sclera can be affected
by transscleral (intraocular) pressure.67 The effects of pressure, however, become a significant
consideration in the delivery of high-molecular-weight compounds. Past and ongoing
experiments suggest that the sclera, by virtue of its large surface area, accessibility, and
relatively high permeability, may indeed provide a useful route for delivering drugs to tissues
in the posterior of the eye.
Joan W. Miller, MD, reviewed photodynamic drug delivery. Photodynamic therapy is a
treatment modality that relies on a photosensitizer agent delivered locally or systemically that
localizes more or less selectively to the target tissue and is activated by light. It results in a
cascade of chemical reactions that injure the target tissue.68,69 Localization has been based
primarily on characteristics of the target tissue and the photosensitizer molecule. Leaky
neovascularization in tumors or CNV permit photosensitizers to pass through the vasculature.
69 In addition, rapidly proliferating tissues such as the endothelium in CNV has greater LDL
receptor expression, and lipophilic photosensitizers associated with serum lipoproteins such
as LDL may be taken up selectively by proliferating tissue. Hydrophobic photosensitizers may
be formulated for solubility and passive targeting using oil-based emulsions, liposomes,
inclusion complexes, organic solvents, and serum lipoproteins. Selective targeting may be
accomplished using monoclonal antibodies, antibody fragments, or peptides. Photodynamic
therapy, using the benzoporphyrin derivative verteporfin, is relatively selective in treating
CNV70 as a liposomal formulation or as a lipoprotein-associated therapy. Animal studies have
demonstrated that this selectivity may be increased through the conjugation of verteporfin with
peptide-targeting vascular endothelial growth factor receptor (VEGFR)-2.71 Selective
targeting may improve the effectiveness of photodynamic therapy for ocular
neovascularization and other disorders.
Ocular Tissue Dissection, Modeling, and Ocular Tissue Assays
Martin Friedlander, MD, discussed the need for better means of administration of agents to the
retina. Present methods of treatment are grossly inadequate; he proposed that cell therapies in
certain instances might be more effective than drug therapies. For example, CNV is
substantially more complicated than presently recognized; hence, a therapeutic goal must
include substantially more than the obliteration of new blood vessels. Because age-related
macular degeneration frequently comprises geographic atrophy as well as subretinal fibrosis,
other tissues must also be given equal consideration in tissue destruction. Although well
intended, current therapies are not without risk; they could well enhance the progression of
destructive retinal diseases. Thus, it is essential that any proposed therapy protect all viable
retinal components and at the same time control and/or diminish the pathologic dangers that
stem from the development of CNV. To this end, Friedlander proposed a new goal: therapies
for CNV should be targeted toward maintenance and improvement of structural integrity of
immature blood vessels.
As an alternative to current methods of treatment, Friedlander cited recent work in which mouse
or human autologous bone marrow or cord blood-derived hematopoietic stem cells are used to
selectively target sites of neovascularization and gliosis where they provide vasculotrophic
effects. Moreover, endothelial progenitor cells have been shown by his laboratory to rescue
retinal blood vessels that would degenerate under ordinary circumstances. The same therapy
also exerted remarkable neurotrophic rescue effects. Freidlander proposed that targeted
progenitor cells could well prove useful in a variety of conditions because of their angiostatic
and neurotrophic properties. An additional potential use may be work on animal models of
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retinopathy of prematurity. Freidlander also mentioned a Trojan horse concept in which
targeted progenitor cells could carry lethal agents directly to neoplasms.
Matthew LaVail, PhD, presented studies on retinal neuroprotection, focused mainly on the
neuroprotective effects of ciliary neurotrophic factor (CNTF). His standard experimental
procedure is to subject albino rodents to a light-induced damage protocol. Under this protocol,
absent any treatment, widespread photoreceptor degeneration occurs. Intraocular injection of
CNTF confers remarkable protection against light-induced damage. Protection is best afforded
by pretreatment, as treatment during or after the light-damage protocol begins is remarkably
less effective. CNTF also affords some retinal protection in rodents and dogs with an inherited
retinal degeneration. Although his laboratory has specialized in single bolus injections, LaVail
briefly reviewed the work of others on long-term, sustained administration of CNTF by
encapsulated cell technology (ECT) and by gene therapy. In the case of ECT, a specific device
containing genetically engineered cells is inserted into the vitreous cavity. The cells are housed
within a hollow cylinder with a wall of a semipermeable membrane. Pore size is such that low-
molecular-weight proteins can diffuse outward but large proteins such as IgG cannot enter.
Devices of this sort have been implanted in Irish setter dogs with an inherited retinal
degeneration for greater than 6 months. At the end of that time, dogs so treated demonstrated
remarkable retinal protection. When the device was explanted, CNTF production, although
somewhat diminished, was still clearly evident.
Even though gene therapy has been used only to a limited extent in animal models of retinal
degeneration, several lessons from it are now clear. First, as Jean Bennett, MD, PhD, and her
colleagues have shown for dogs with Leber congenital amaurosis (LCA), gene therapy can
result in a sustained restoration of vision. Second, sustained production of a rescue agent that
results from gene therapy can achieve beneficial results in selected instances where single
injection protocols have failed to show such benefit. Several aspects of treatment with CNTF
require special mention. First, not all CNTFs are the same; there are remarkable differences in
efficacy that are species specific. Second, under certain circumstances CNTF can depress both
visual acuity and electroretinographic responses in rodents; thus, there is a potential for toxicity
that requires further exploration. Third, the mechanism of action of the agent is not fully
understood at present; the best evidence to date indicates that CNTF acts through Müller cells.
Robert Marc, PhD, described methods he has developed for high-resolution imaging of specific
classes of retinal neurons. Using immunocytochemical methods on ultrathin tissue sections,
his laboratory has pioneered visualization of functional expression of several classes of retinal
neurons. Such methodology can be used to map common retinal neurochemicals: taurine and
glutamate among them.72
Using these technologies, his laboratory has performed quantitative mapping and
computational reconstruction to achieve insight into dynamic retinal function.72 Quoting an
original observation by Ann Milam, PhD, that a retina undergoing deafferentation as a result
of photoreceptor degeneration begins to remodel, Marc documented with clarity the successive
pathologic derangements that occur. In effect, he demonstrated that in the retina, just as in
brain, the loss of neuronal input is followed by a series of neuropathologic events that can be
visualized in his computational reconstructions. Illustrating this phenomenon with
observations on retinal neuropathology in rodent models of retinal degeneration, he has
documented “deconstruction of retinal phenotype.” Implying that change is widespread, he
described studies from the laboratory of Connie Cepko, MD; gene arrays from mutant mouse
retina evidence change in the expression of “every” gene.
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Iontophoresis, Electroporation, Electrophoresis, and Photoacoustic Delivery
Daniel Palanker, PhD, Francine Behar-Cohen, MD, PhD, Kevin Li, PhD, and John Nickerson,
PhD, described novel technologies for improved drug delivery via electric fields.
It is known that voltages and currents that are too high result in vaporization, burns, and death.
Vasoconstriction occurs at relatively low currents, and the duration needed for pooling of blood
and thrombus formation after vasoconstriction is not high. However, under control, electrical
fields can be used to deliver drugs to specific targets in the cell and subcellular compartments
without damage to surrounding tissues.
Examples were presented that illustrated successful delivery of many different therapeutic
drugs currently used in medical practice. Animal studies demonstrated how current and ions
flow through the eye. An illuminating study was the use of MRI to monitor iontophoresis in
real time.73 Manganese ions exhibit an MRI signature, making them suitable for monitoring
the movement of atomic scale particles in an electric field in eye tissue. In both transcorneal
and transscleral iontophoresis, manganese ions moved macroscopic distances in the eye of a
live rabbit. Results showed current paths in the living eye and penetration of manganese ions
through the sclera and into the vitreous during transscleral iontophoresis. During transcorneal
iontophoresis, manganese ions are distributed throughout the anterior chamber.
Examples of iontophoresis were also presented. David Maurice advocates the use of
iontophoresis to deliver drugs intraocularly; more than 300,000 patients in Europe have been
treated with iontophoresis for eye disease.74 Antibiotics, antifungals, antivirals, anti-
inflammatories, and analgesics have also been delivered by ocular iontophoresis.75 Parel et
al.76,77 have developed a constant current device that adjusts voltage according to changes in
tissue resistance during treatment. They found that transscleral iontophoresis can be safe with
a current density up to 50 mA/cm2 for 5 minutes. This current density is spread out over a large
area of the corneal limbus. Their work highlights the change in properties of tissue during
iontophoresis. Barrier alteration in a tissue may be the principal mechanism by which drug
transport or permeability is increased during and after iontophoresis. Proper electrode
placement is important in transscleral iontophoresis, and the pars plana location allows the
most drug to be delivered into the vitreous. It remains to be determined whether this location
is most susceptible to barrier breakdown or if it simply has the least resistance to start with.
78 Ocular iontophoresis can be used to create a drug depot in the sclera that subsequently
undergoes sustained drug release. This strategy reduces the number and frequency of
iontophoretic treatments. Li's group delivered triamcinolone acetonide phosphate into the
rabbit eye from one electrode and calcium ions from the other at the same time (Higuchi JW,
et al. IOVS 2007;48:ARVO E-Abstract 5822). Calcium ions and the phosphate moiety on the
triamcinolone acetonide analogue precipitated when they came into contact, forming a
reservoir of drug in the sclera. The precipitate dissolved slowly and ameliorated symptoms in
an experimental model of uveitis.
A strength of iontophoresis is that over short distances, high concentrations of drugs can be
delivered in a few minutes. Iontophoresis is the method of choice for charged drugs, which
otherwise can be problematic in crossing membranes or hydrophobic barriers.
Weaknesses of iontophoresis include the impracticality of transporting drugs from the anterior
surface to the posterior by iontophoresis due to the weak electric field applied across the eye,
the low mobility of drugs, and short duration of treatment. Anterior segment structures may
be more sensitive to electric field strength than posterior components. For delivery to the
posterior segment, it is suggested that the route be transscleral, not transcorneal.
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Electroporation has been used most successfully to transfect DNA, RNA, or nucleic acid
analogues into eukaryotic and bacterial cells in laboratory experiments. In vitro transfection
efficiencies are quite high, 50% to 90%, depending on the cell line, in eukaryotic cells and up
to 1010 successful transformants per microgram of plasmid DNA in bacteria. Given these high
success rates, it seems attractive to test electroporation in vivo in living animals. There are
difficulties in translating this technology into clinical practice.
Examples of electroporation include: (1) A reporter protein expressed in RGCs after delivery
by intravitreous injection of naked plasmid and electroporation79; (2) subretinal injection of
a plasmid and electroporation in newborn rats or mice resulted in widespread transduction of
retinal cells80,81; (3) electroporation pulses administered with a 90° rotation between sets of
pulses were more effective than without rotation of the field. The rotation increased the surface
area of the cell membrane that was exposed to the electric field82; and (4) under typical
conditions of electroporation, heat buildup is negligible, but under other conditions the change
in temperature can be sharp and so great that the nearby medium vaporizes. Under exceedingly
specialized circumstances, this vaporization is advantageous. Rapid vaporization leads to
microbubble formation and collapse that initiates a shockwave. The shockwave stretches the
plasma membrane of a nearby cell, promoting pore formation. The resulting electric pulse and
shockwave are synchronized, which yields increased transfection by 1,000- to 10,000-fold over
standard electroporation. This was demonstrated recently in RPE cells in living rabbits.83
A strength of electroporation is that reporter gene expression peaks in a tight range of field
strengths (100–200 V/cm), while increasing pulse length up to a point increases expression;
100 to 200 V/cm at 20 to 150 ms gives approximately 30% of cells transfected in vivo. In many
experiments, reporter expression increases linearly up to maximum dose of plasmid that is
tested, indicating that the most effective dosage is not routinely reached. By increasing the
concentration of plasmid DNA, the transfection efficiency should be markedly improved.
79-82
A weaknesses of electroporation is that the maximum safe threshold voltage is reached
abruptly. Transfection efficiency seems low compared to some viral delivery systems.
In summary, electric field–tissue interactions are complex and poorly understood, and their
applications require optimization for each particular ocular target. The use of electric fields
should be given consideration when simpler delivery approaches fail. Electric fields offer the
unique advantage of transiently and reversibly breaching any membrane of the cell. Provided
that great care is taken to minimize cellular damage by the electric field, iontophoresis and
electroporation are delivery approaches worthy of further consideration.
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